Introduction

Testicular cancer is an uncommon malignancy but remains the most common solid organ malignancy in men aged 15–35 years. Long term cure rates are excellent for even advanced stage disease with a multimodal and multidisciplinary management strategy.

Retroperitoneal lymph node dissection (RPLND) forms part of the treatment algorithm for a subset of men with testicular cancer and contributes to the high cure rates that these men can achieve. This article aims to review the indications and variations in surgical technique, as well as review published outcomes.

Indications

Broadly speaking, RPLND can be undertaken in two distinct settings: primary surgical treatment and the post-chemotherapy or salvage setting. While the surgical approach in these cases is similar, the rationale behind the surgery and outcomes may differ.

Primary RPLND

Clinical stage I disease

In the management of stage I non seminomatous germ cell tumour (NSGCT), RPLND may be offered following...
orchidectomy as an alternative to surveillance or adjuvant chemotherapy. Up to 30% of patients with stage 1 disease may have subclinical metastatic disease at the time of presentation. Primary RPLND in this setting offers diagnostic/staging value, in addition to a therapeutic benefit for those with metastatic disease.

Given the highly chemosensitive nature of NSGCT and the excellent results achieved with surveillance or adjuvant chemotherapy, the role for primary RPLND in stage I disease has reduced over time. A randomised controlled trial comparing RPLND with a single course of adjuvant BEP for stage 1 NSGCT demonstrated a 7% reduction in recurrence at 2 years in favour of the chemotherapy group (1).

Advantages of a primary approach to RPLND include the ability to more routinely offer minimally invasive and nerve sparing techniques, avoidance of chemotherapy toxicity and a less intensive follow up regimen with lower exposure to ionising radiation from surveillance CT imaging. Likewise, in a population at high risk for non-compliance with a surveillance protocol, primary RPLND may offer a safer management strategy.

Clinical stage II disease
There is a general consensus that for metastatic germ cell tumour, first line therapy should consist of chemotherapy due to the chemosensitive nature of the tumour. The exception to this is stage IIA NSGCT or pure teratoma without tumour marker elevation in which primary RPLND or surveillance could be offered (2). In the case of surveillance, persistence or growth of a retroperitoneal mass without corresponding increase in tumour markers can be an indication for proceeding with RPLND.

Post chemotherapy (Salvage) RPLND
Seminoma
A residual mass post chemotherapy for metastatic seminoma requires careful evaluation with imaging. FDG PET has a role in assessing the mass, and has a high negative predictive value, especially in masses >3 cm (3). RPLND is rarely required as salvage chemotherapy is the preferred approach for an enlarging or PET avid mass. In the case of RPLND proceeding, it should be performed in a high-volume centre, as the intense fibrosis in these cases complicates the operative approach.

Non seminomatous germ cell tumour
Following chemotherapy for metastatic NSGCT, resection of a residual mass with normal tumour markers may be required. Although it is recognised that a significant portion of these will contain no viable tumour (40%), the indication for surgery is that around 50% do contain teratoma and 10% viable germ cell tumour (4).

Generally, a residual mass >1 cm in size is indication for proceeding to RPLND, while controversy exists for smaller masses. A surveillance protocol may be used as an alternative, however, patients must be counselled that there is a recognised recurrence rate of up to 9% (5).

The surgical approach should include a bilateral or modified template dissection in addition to resection of the residual mass. Complex masses may require additional intervention including en bloc resection of the kidney, psoas or great vessels with substitution grafting if needed. In these cases, a multidisciplinary approach to surgery is required.

Technique
Preoperative preparation
Appropriate perioperative counselling is mandatory as would be expected for any major operation. In a fertile cohort of men, the risks to antegrade ejaculation and the role and success of a nerve sparing procedure must be discussed. Routine perioperative assessment should be performed, including a group and hold or crossmatch. In patients who have received bleomycin containing chemotherapy regimens, preoperative lung function testing and anaesthetic assessment are necessary. Bleomycin induced lung disease can lead to interstitial pneumonitis and fibrosis. Intra-operative management to minimise pulmonary complications include minimising fluid overload and the use of air rather than supplemental oxygen for ventilation.

Large or complex masses or those involving other organs may require additional procedures including nephrectomy and aortic or vena caval resection and substitution. Adequate preparation should include the presence or availability of other specialty surgical units in cases with anticipated difficulties.

RPLND templates
Various templates have been described for the limits of RPLND, and their use and extent continue to generate controversy in the management of germ cell tumours. Advantages of using template dissections include limiting
morbidity of the procedure and preserving antegrade ejaculation, however, the main drawback is the potential for inadequate dissection leaving a patient at risk of relapse.

The rationale for modified template dissections is based on the well understood pattern of landing zones of lymphatic drainage from testicular primaries. The decision to pursue a modified template dissection depends on the laterality of the primary along with the presence and size of any retroperitoneal mass.

Data suggest that the use of template dissections in appropriately selected cohorts may offer durable long-term outcomes with a reduction in morbidity when compared with more extensive dissections (6).

**Bilateral template**

The described boundaries of the bilateral template dissection include both ureters laterally, renal hilum superiorly and the common iliac arteries inferiorly. Approach is as described below. Nodal packets obtained include paraaortic, interaortocaval, paracaval and gonadal vein ipsilateral to the primary tumour down to the level of the deep inguinal ring.

**Right modified template**

Boundaries of right modified template include the ureter laterally, periaortic lymphatics above IMA medially, renal hilum superiorly and right common iliac artery inferiorly.

Exposure is obtained by incising the root of the small bowel mesentery as described above. Nodal packets obtained include paracaval, interaortocaval and right gonadal vein.

**Left modified template**

Likewise, boundaries of left modified template include the ureter laterally, periaortic lymphatics above IMA medially, renal hilum superiorly and left common iliac artery inferiorly.

Adequate exposure can be obtained by medial mobilisation of the left colon.

Nodal packets removed include the para-aortic and left gonadal vein.

**Open RPLND**

The patient is placed in the supine position and a midline laparotomy is performed, with division of the falciform ligament. Exposure is achieved with a self-retaining retractor such as the Omnitract system. Rarely, a thoracoabdominal approach may be used for large or complex masses with anticipated difficulties.

The retroperitoneum can be accessed by incising the posterior peritoneum along the root of the small bowel mesentery from caecum to ligament of Treitz. For larger masses, the incision can continue around caecum and along the line of Toldt to adequately mobilise the right colon. Mobilisation of the left colon medially may be required for some cases with large para-aortic masses.

The “split and roll” technique is generally used over the great vessels to safely identify critical branches and tributaries. The optimal plane of dissection is on the adventitia of the great vessels, which minimises the risks of positive margins on tumour or inadvertent vascular damage. Dissection commences over the aorta inferior to the crossings of the left renal vein, then is continued caudally to identify the origin of the inferior mesenteric artery (IMA). The IMA is usually preserved in right modified template dissection but may be required to be sacrificed in bilateral dissection to obtain adequate exposure. Ligation of larger lymphatic channels should be performed throughout to reduce the risk of postoperative chyle leak.

Lymphatics overlying the aorta are rolled medially to identify the right lumbar arteries, which are ligated to access to the interaortocaval packet. Likewise, the tissue overlying the aorta is rolled laterally to identify and ligate the left lumbar arteries to obtain complete vascular control of the abdominal aorta below the renal hilum. The ligation of lumbar arteries does incur the risk of devascularisation of the spinal cord with resultant paraplegia but is considered essential for complete clearance of the retro-aortic lymph nodes.

A similar split and roll technique is used over the IVC commencing at the level of the right renal hilum, then carried caudally. The origin of the right gonadal vein and the highly variable lumbar veins need to be identified, all of which are ligated to obtain vascular control of the IVC.

Following adequate exposure and vascular control, the required lymph node packets can then be harvested. Posterior control of the lumbar veins and arteries is required as the nodal packets are dissected free from the vertebral ligaments and muscles. Care must be taken to protect the sympathetic trunk during this dissection.

**Nerve sparing technique**

Nerve sparing RPLND focusses on preservation of the hypogastric plexus and its branches, which course over the anterior aorta and aortic bifurcation. Nerve sparing can
preserve ejaculatory function in 99–100% of patients.

The left sympathetic chain is identified running laterally to vertebral column. Individual post ganglionic fibres are identified exiting the sympathetic chain and are sharply dissected and elevated with vessel loops. The right sided postganglionic fibres are identified emerging from the lateral surface of the IVC in the interaortocaval region and are likewise dissected and slung with vessel loops. The lymphatic tissue remaining below the identified nerves is then removed in a standard fashion to complete the dissection (7).

Nerve sparing in the post chemotherapy setting becomes more difficult due to fibrosis of tumour and surrounding tissue but may still be possible for those with limited disease. Alternatively, a selective or unilateral nerve spare may be performed, although rates of ejaculatory preservation are lower compared to bilateral nerve sparing. For cases in which the resectability of tumour is in doubt, the primary oncological outcome of the operation must not be compromised in attempting nerve preservation.

**Minimally invasive RPLND**

Traditionally RPLND was routinely performed in an open fashion, however, in recent years the development of minimally invasive options has created the option of a less morbid procedure. Given the oncological principles underlying the procedure, it is critically important that the quality and extent of lymph node dissection is not compromised in striving for a minimally invasive approach. When minimally invasive approaches were developed initially, a diagnostic or staging approach was taken due to the technical difficulties of the procedure. However, in contemporary series, a therapeutic approach is pursued, with the aim to match the extent of nodal dissection seen with an open approach.

Laparoscopic RPLND (L-RPLND) was first described in the 1990’s (8) and was taken up in high volume centres around the world. Retrospective series suggested a benefit of shorter hospital stay and faster return to normal activities when compared with open approach, along with high rates of preservation of antegrade ejaculation (95–100%; Table 1) (32).

Introduction of robotic-assisted RPLND (RA-RPLND) followed in the 2000s with the implementation of robotics in other areas of urologic oncology, offering potential advantages compared to laparoscopic techniques for a technically demanding operation (33). Safety and feasibility have been demonstrated with the publication of several case series (28,29).

Case series of L-RPLND suggest a comparable staging accuracy and relapse rate to open RPLND in stage I disease, however, no randomised comparisons exist (Table 1). Series of RA-RPLND are mostly limited to small numbers confirming safety and feasibility. The use of minimally invasive approaches in stage II or post chemotherapy setting has been investigated in a variety of small case series, confirming feasibility. Follow up in these series is short, requiring larger series with longer follow up to further investigate oncologic outcomes. It is likely that surgeon expertise will limit the utilisation of minimally invasive approaches to this relatively rare procedure.

**Post-operative care**

Routine post-operative care in a high dependency unit is recommended. Fluid administration should be limited in patients who have received bleomycin chemotherapy pre-operatively. Mechanical and chemical DVT prophylaxis is mandatory in addition to early mobilisation as appropriate. Generally a clear fluid diet is commenced initially and upgraded as tolerated.

**Conclusions**

RPLND forms an integral part of the management of a subset of men with metastatic germ cell tumours. While historically, the open approach carried a significant burden of morbidity, newer, minimally invasive approaches have aimed to reduce morbidity while still achieving the oncological clearance needed. Regardless of the approach used, oncological principles should be adhered to. These men should be managed in a multidisciplinary fashion and preferably in high volume centres to achieve best possible outcomes.
Table 1 Comparison of open, laparoscopic and robotic retroperitoneal lymph node dissection

<table>
<thead>
<tr>
<th>Group</th>
<th>Year</th>
<th>N</th>
<th>CS I (n)</th>
<th>CS II (n)</th>
<th>Timing of RPLND</th>
<th>Nerve sparing</th>
<th>OT time (min)</th>
<th>EBL (mL)</th>
<th>LOS (days)</th>
<th>Cx rate (%)</th>
<th>Recurrence free rate (%)</th>
<th>Antegrade ejaculation rate (%)</th>
<th>Follow up duration (months)</th>
<th>Recurrence rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open RPLND (N=6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Busch (9)</td>
<td>2012</td>
<td>21</td>
<td>PC-RPLND</td>
<td>Both</td>
<td>232</td>
<td>&gt;500</td>
<td>11.5</td>
<td>38.0</td>
<td>(28.5% Clavien III)</td>
<td></td>
<td></td>
<td>54.5</td>
<td>14.2</td>
<td></td>
</tr>
<tr>
<td>Subramanian (10)</td>
<td>2010</td>
<td>112</td>
<td>PC-RPLND</td>
<td></td>
<td>96</td>
<td>1000</td>
<td>6</td>
<td>12</td>
<td>41</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luz (11)</td>
<td>2010</td>
<td>81</td>
<td>PC-RPLND</td>
<td>33 bilateral, 9 unilateral, 31 no nerve sparing</td>
<td>366</td>
<td>765</td>
<td>8.5</td>
<td>27.4</td>
<td>(15.4% Clavien III)</td>
<td></td>
<td></td>
<td>47</td>
<td>9.6</td>
<td></td>
</tr>
<tr>
<td>Li (12)</td>
<td>2019</td>
<td>64</td>
<td>PC-RPLND</td>
<td>88.9% bilateral template</td>
<td>375</td>
<td>825</td>
<td>7</td>
<td>39.7</td>
<td>11</td>
<td>81</td>
<td>NA</td>
<td></td>
<td>18.4</td>
<td></td>
</tr>
<tr>
<td>Williams (13)</td>
<td>2010</td>
<td>98</td>
<td>Primary RPLND</td>
<td></td>
<td>188</td>
<td>184</td>
<td>4.1</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicolai (14)</td>
<td>2009</td>
<td>91</td>
<td>PC-RPLND</td>
<td></td>
<td>226</td>
<td>413</td>
<td>4.8</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1 (continued)
<table>
<thead>
<tr>
<th>Group</th>
<th>Year</th>
<th>N</th>
<th>CS I (n)</th>
<th>CS II (n)</th>
<th>Timing of RPLND</th>
<th>Nerve sparing (Uni/bilat)</th>
<th>OT time (min)</th>
<th>EBL (mL)</th>
<th>LOS (days)</th>
<th>Cx rate (%)</th>
<th>Positive LN's (%; no. of nodes positive)</th>
<th>Recurrence free rate (%)</th>
<th>Antegrade ejaculation rate (%)</th>
<th>Follow up duration (months)</th>
<th>Recurrence rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laparoscopic RPLND (N=13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X; 20 nodes 13.3 in Node-, (12 N+, 12 N-)</td>
<td>97</td>
<td>72</td>
<td>6.6</td>
<td></td>
</tr>
<tr>
<td>Bhayani (15)</td>
<td>2003</td>
<td>29</td>
<td>29</td>
<td>0</td>
<td>Modified template, 2 cycles CTx for node +</td>
<td>258</td>
<td>241</td>
<td>2.6</td>
<td></td>
<td></td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
<tr>
<td>Busch (9)</td>
<td>2012</td>
<td>46</td>
<td></td>
<td></td>
<td>PC-RPLND</td>
<td>Both</td>
<td>212</td>
<td>&gt;500</td>
<td>6</td>
<td>7.6%</td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
<tr>
<td>Calestroupat (16)</td>
<td>2009</td>
<td>26</td>
<td></td>
<td></td>
<td>Primary</td>
<td>Unilateral</td>
<td>183</td>
<td>400</td>
<td>5</td>
<td></td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
<tr>
<td>Cresswell (17,18)</td>
<td>2008</td>
<td>87</td>
<td>87</td>
<td></td>
<td>Primary RPLND, 24 adjuvant CTx</td>
<td>Unilateral</td>
<td>226</td>
<td>3.5</td>
<td>3.3</td>
<td></td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
<tr>
<td>Janetschek (18)</td>
<td>2001</td>
<td>125</td>
<td>49</td>
<td></td>
<td>Primary RPLND</td>
<td>Unilateral</td>
<td>226</td>
<td>3.5</td>
<td>3.3</td>
<td></td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
<tr>
<td>Albqami (19)</td>
<td>2005</td>
<td>59</td>
<td></td>
<td></td>
<td>Primary RPLND</td>
<td>Unilateral</td>
<td>234</td>
<td>3.8</td>
<td>3.3</td>
<td></td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
<tr>
<td>Steiner (20)</td>
<td>2008</td>
<td>42</td>
<td>19</td>
<td></td>
<td>Primary RPLND, 24 adjuvant CTx</td>
<td>Unilateral</td>
<td>226</td>
<td>3.5</td>
<td>3.3</td>
<td></td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
<tr>
<td>Steiner (21)</td>
<td>2013</td>
<td>100</td>
<td>100</td>
<td></td>
<td>PC-RPLND, NSGCT</td>
<td>Bilateral</td>
<td>241</td>
<td>84</td>
<td>3.9</td>
<td></td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
<tr>
<td>Castillo (22)</td>
<td>2011</td>
<td>164</td>
<td>164</td>
<td>0</td>
<td>Primary RPLND</td>
<td>Unilateral</td>
<td>135</td>
<td>50</td>
<td>2</td>
<td>10</td>
<td>LN yield 7 (%; Clavien III)</td>
<td>13.3 in Node-, (12 N+, 12 N-)</td>
<td>21.7 (19.5%)</td>
<td>8.6 (76.6 months mean disease-free survival)</td>
<td>30.1</td>
</tr>
</tbody>
</table>

Table 1 (continued)
<table>
<thead>
<tr>
<th>Group</th>
<th>Year</th>
<th>N</th>
<th>CS I (n)</th>
<th>CS II (N)</th>
<th>Timing of RPLND</th>
<th>Nerve sparing (Uni/bilat)</th>
<th>OT time (min)</th>
<th>EBL (mL)</th>
<th>LOS (days)</th>
<th>Cx rate (%)</th>
<th>Positive LNs (%, no. of nodes positive)</th>
<th>Recurrence free rate (%)</th>
<th>Antegrade ejaculation rate (%)</th>
<th>Follow up duration (months)</th>
<th>Recurrence rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rassweiler (23)</td>
<td>2000</td>
<td>34</td>
<td>10 CTx</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Rassweiler (23)</td>
<td>2000</td>
<td>34</td>
<td>10 CTx</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Corvin (24)</td>
<td>2005</td>
<td>18</td>
<td>7 CTx</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Nicolai (25)</td>
<td>2017</td>
<td>221</td>
<td>221</td>
<td>Primary RPLND</td>
<td>Unilateral</td>
<td>200</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Robotic primary RPLND (N=4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Harris (26)</td>
<td>2015</td>
<td>16</td>
<td>–</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Cheney (27)</td>
<td>2015</td>
<td>10</td>
<td>–</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Stepanian (28)</td>
<td>2016</td>
<td>11</td>
<td>–</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Pearce (29)</td>
<td>2017</td>
<td>42</td>
<td>–</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Robotic PC-RPLND (N=5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Cheney (27)</td>
<td>2015</td>
<td>8</td>
<td>–</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Stepanian (28)</td>
<td>2016</td>
<td>4</td>
<td>12 unilateral</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Kamel (30)</td>
<td>2016</td>
<td>12</td>
<td>–</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Singh (31)</td>
<td>2017</td>
<td>13</td>
<td>–</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
<tr>
<td>Li (12)</td>
<td>2019</td>
<td>30</td>
<td>19</td>
<td></td>
<td>Nerv spARING</td>
<td>Uni/bilat</td>
<td></td>
<td>EBL</td>
<td>LOS</td>
<td>Cx rate (%)</td>
<td>Positive LNs (%, no. of nodes positive)</td>
<td>Recurrence rate (%)</td>
<td>Antegrade ejaculation rate (%)</td>
<td>Follow up duration (months)</td>
<td>Recurrence rate (%)</td>
</tr>
</tbody>
</table>

RPLND, retroperitoneal lymph node dissection; NSGCT, non-seminomatous germ cell tumour; PC, post-chemotherapy; CTx, chemotherapy; CS, clinical stage; OT, operating theatre; EBL, estimated blood loss; LOS, length of stay; Cx rate, complication rate; LN, lymph node.
Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Translational Andrology and Urology for the series “Surgery for Urologic Cancers”. The article has undergone external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-2019-suc-18). The series “Surgery for Urologic Cancers” was commissioned by the editorial office without any funding or sponsorship. SS served as the unpaid Guest Editor of the series and serves as an unpaid editorial board member of Translational Andrology and Urology from Jul 2018 to Jun 2020. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


